Cycling to cancer with cyclin D1

Cancer Biology and Therapy

Volumn 1, Issue 3, 2002, Pages 226-231

  Diehl, J Alan ^a  

^a NONE

Author keywords

Cancer; Cell cycle; Cyclin D1; Restriction point control

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE; ONCOPROTEIN; RETINOBLASTOMA PROTEIN; UBIQUITIN;

CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHOSPHORYLATION; REVIEW;

ANTINEOPLASTIC AGENTS; CYCLIN D1; CYCLIN-DEPENDENT KINASES; G1 PHASE; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; S PHASE; UBIQUITINS;

EID: 0013439945     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.72     Document Type: Review

References (78)

1. Norbury C, Nurse P. Animal cell cycles and their control. Anual Reviews of Biochemistry 1992; 61:441-70.
2. Reed SI. The role of p34 kinases in the G1 to S-phase transition. Annual Reviews of Cell Biology 1992; 8:529-61. (Pubitemid 23001007)
3. Morgan DO. Principles of cdk regulation. Nature 1995; 374:131-4.
4. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-63.
5. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
6. Sherr CJ. Mammalian G1 cyclins. Cell 1993; 73:1059-65.
7. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S hase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994; 14:1669-79.
8. Quelle DE, Ashmun RA, Shurtleff SE, Kato JY, Bar-Sagi D, Roussel MF, et al. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 1993; 7:1559-71. (Pubitemid 23234349)
9. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259:1908-12.
10. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato J-Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994; 14:2066-76. (Pubitemid 24074604)
11. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991; 65:701-13.
12. Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signaling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Current Biology 1997; 7:219-21. (Pubitemid 27167420)
13. Mulcahy LS, Smith MR, Stacey DW. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 1995; 313:241-3.
14. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, et al. Ras signaling linked to the cell-cycle machinery by the retinoblasoma protein. Nature 1997; 386:177-81. (Pubitemid 27131445)
15. Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad SciUSA 1998; 95:1091-6.
16. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal- regulated kinase 1 (ERK1) is required for the continued expression of cyclin D in G1 phase. Biochem J 1997; 326:61-8. (Pubitemid 27386918)
17. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, et al. Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995; 270:23589-97.
18. MAPK pathway. J Biol Chem 1996; 271:20608-16.
19. Winston JT, Coats SR, Wang Y-Z, Pledger WJ. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996; 12:127-34. (Pubitemid 26041248)
20. Aktas H, Cai H, Cooper GM. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27. Mol Cell Biol 1997; 17:3850-57. (Pubitemid 27281860)
21. Kerkhoff E, Rapp UR. Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol 1997; 17:2576-86. (Pubitemid 27175139)
22. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3b regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511. (Pubitemid 28553242)
23. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11:957-72. (Pubitemid 27199876)
24. Rodriguez-Viciana P, Warne PH, Dhand R, Gout I, Fry MJ, Waterfield M, et al. Phosphatidylinositol-OH-kinase as a direct target of Ras. Nature 1994; 370:527-32.
25. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3-4-bisphosphate. Science 1997; 275:665-8. (Pubitemid 27061333)
26. Franke TF, Yang TO, Chan K, Datta A, Kazlauskas DK, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PKGF-activated phosphatidylinositol 3-kinase. Cell 1995; 81:727-36.
27. Klinghoffer RA, Duckworth B, Valius M, Cantley L, Kazlauskas A. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins -which influence ras activity. Mol Cell Biol 1996; 16:5909-14.
28. Matsushime H, Ewen ME, Strom DK, Kato J-Y, Hanks SK, Roussel MF, et al. Identification and properties of an atypical catalytic subunit (p34PSKJ3/CDK4)for mammalian D-type G1 cyclins. Cell 1992; 71:323-34.
29. Vanhaesebroeck B, Leevers SJ, Panayotou B, Waterfield M. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997; 22:267-72. (Pubitemid 27310948)
30. Cross DAE, Alessi DR, Cohen P,jelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-89.
31. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275:661-665. (Pubitemid 27061332)
32. Stambolic V, Woodgett JR. Mitogen inactivation of glycogen synthase kinase-3β in intact cells via serine 9 phophorylation. Biochem J 1994; 303:701-4. (Pubitemid 24325998)
33. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30.
34. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999; 98:859-69. (Pubitemid 29446902)
35. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27kip1, a cyclin-cdk inhibitor links transforming growth factor beta and contact inhibition to cel cycle arrest. Genes Dev 1994; 8:9-22.
36. Kip1 a cyclin-cdk inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78:59-66.
37. Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995; 9:1831-45.
38. Kip1 coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev 1997; 11:492-503.
39. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78:67-74. (Pubitemid 24228301)
40. Kato J-Y, Matsuoka M, Strom DK, Sherr CJ. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 1994; 14: 2713-21. (Pubitemid 24108252)
41. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, et al. New functional activities for the p21 family of inhibitors. Genes Dev 1997; 11:847-62. (Pubitemid 27175292)
42. Cheng C, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, et al. The p21Cip1 and p27Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18:1571-83.
43. cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 2001; 277:8517-23.
44. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991; 350:512-15. (Pubitemid 21912266)
45. Williams ME, Swerdlow SH, Meeker TC. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. Leukemia 1993; 9:1437-40. (Pubitemid 23291087)
46. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-22.
47. Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001; 2:207-18. (Pubitemid 33010796)
48. Yamanouchi H, Furihata M, Fujita J, Murakami H, Yoshinouchi T, Takahara J, et al. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: an immunohistochemical study. Lung Cancer 2001; 1:3-8. (Pubitemid 32012597)
49. Ikeguchi M, Sakatani T, Ueta T, Kaibara N. Cyclin D1 expression and retinoblastoma gene protein (pRb) expressin in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2001; 127:531-6. (Pubitemid 32757486)
50. Izzo JG, Papadimitrakopoulou VA, Li XQ, Ibarguen H, Lee JS, Ro JY, et al. Dysregulated cyclin D1 early in head and neck tumorigenesis:in vivo evidence for an association with subsequent gene amplification. Oncogene 1998; 17:2113-22.
51. Bartkova J, Lukas J, Muller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995; 55:949-56.
52. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, et al. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 1997; 57:1634-7. (Pubitemid 27199649)
53. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv Cancer Res 1996; 68:67-108. (Pubitemid 26099813)
54. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN, et al. Aberrant expression of G1/S regulators is a frequent event in sporadic pituitary adenomas. Carcinogenesis 2001; 22:1149-54. (Pubitemid 32737328)
55. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN, et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research 1999; 21:33-9.
56. Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Breast Cancer Res Treat 1998; 52:1-15. (Pubitemid 29056081)
57. Fantl V, Smith R, Brookes S, Dickson C, Peters G. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv 1993; 18:77-94.
58. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369:669-71. (Pubitemid 24199473)
59. Bartkov J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57:353-361. (Pubitemid 24168609)
60. Kong S, Amos CI, Luthra R, Lynch M, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000; 60:249-52. (Pubitemid 30070744)
61. Zheng Y, Shen H, Sturgis EMWLE, Eicher SA, Strom SS, Frazier ML, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001; 22:1195-9. (Pubitemid 32737335)
62. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000; 14:3102-14. (Pubitemid 32015129)
63. Nielsen NH, Loden M, Cajander J, Emdin SO, Landberg G. G1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res Treat 1999; 56:105-12. (Pubitemid 29494828)
64. Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 2002; 277:2207-15. (Pubitemid 34968808)
65. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, et al. Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 1997; 17:5338-47. (Pubitemid 27357632)
66. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997; 88:405-15. (Pubitemid 27131382)
67. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12. (Pubitemid 29297917)
68. Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Mol Cell Biol 1998; 12:2899-911.
69. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998; 396:177-80. (Pubitemid 28523620)
70. Loda MCB, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Medicine 1997; 3:213-34.
71. Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat 2001; 67:15-22. (Pubitemid 32703384)
72. Lau R, Grimson R, Sansome C, Tornos C, Moll UM. Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol 2001; 18:17-23.
73. Chiarle R, Pagano M, Inghirami G. The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Research 2001; 3:91-4. (Pubitemid 32266276)
74. Waf1/Cip1-deficient mice. Cancer Res 2001; 61:6234-8.
75. Jones JM, Cui X-S, Medina D, Donehower LA. Heterozygosity of p21Waf1/Cip1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ 1999; 10:213-22. (Pubitemid 29196657)
76. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001; 411:41017-21.
77. Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 2001; 276:16617-23.
78. Kip1. Genes Dev 1997; 11:1464-78.